Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.70 |
| ▸ | MMP9 | P14780 | 2/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.69 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.69 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.69 |
| ▸ | TTR | P02766 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | ESR1 | P03372 | 2/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naringenin SCHEMBL28072458 | 1.00 | BACE1 (0.70) | BACE1MMP9CYP19A1CYP3A4CYP1A1 | |
| Naringenin SCHEMBL28072460 | 1.00 | BACE1 (0.70) | BACE1MMP9CYP19A1CYP3A4CYP1A1 | |
| Acacetin SCHEMBL891690 | 0.93 | MMP9 (0.71) | BACE1MMP9CYP19A1CYP3A4CYP1A1 | |
| Homoeriodictyol SCHEMBL17651827 | 0.89 | MMP9 (0.72) | BACE1MMP9CYP19A1CYP3A4CYP1A1 | |
| Genkwanin SCHEMBL5469869 | 0.88 | CYP19A1 (0.74) | BACE1MMP9CYP19A1CYP3A4CYP1A1 | |
| Naringenin SCHEMBL20570 | 0.83 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL20571 | 0.83 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL29351357 | 0.83 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL17166263 | 0.83 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 | |
| Naringenin SCHEMBL1048136 | 0.83 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2006083666-A1 | ANTI-INFLAMMATORY SUPPLEMENT COMPOSITIONS AND REGIMENS TO REDUCE CARDIOVASCULAR DISEASE RISKS | A.M. TODD COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | BACE1 3340/4885MMP9 1820/4885CYP19A1 4329/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | BACE1 3340/4885MMP9 1820/4885CYP19A1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.